BCG Vaccine and Complications

Betül BANKOĞLU PARLAKa , Abdurrahman Erdem BAŞARANa , Ayşen BİNGÖLa

aAkdeniz University Faculty of Medicine, Department of Pediatric Chest Diseases, Antalya, Türkiye

ABSTRACT
The BCG vaccine is primarily used to prevent tuberculosis infection and is one of the most widely used childhood vaccines. This review mentions BCG vaccination history, activity, vaccination program, application and complications. Complications that are not accompanied by immunodeficiency are usually localised and most of them regress spontaneously without treatment. Disseminated complications should be noted that BCG dissemination may be the first sign of a patient with primary immunodeficiency.
Keywords: Tuberculosis; prevention; BCG vaccine

Referanslar

  1. Kaufmann SH, Hussey G, Lambert PH. New Vaccines for Tuberculosis. Lancet. 2010;375:2110-9. [Crossref]  [PubMed]
  2. Global tuberculosis report 2022. Geneva: World Health Organization; 2022. Licence: CC BY-NC-SA 3.0 IGO.
  3. United Nations Children's Fund (UNICEF) and the World Health Organization (WHO). Immunization summary: A statistical reference containing data through 2010 (The 2013 edition).
  4. Colditz GA, Berkey CS, Mosteller F, Brewer TF, Wilson ME, Burdick E, et al. The efficacy of BCG vaccination of newborns and infants in the prevention of tuberculosis: Metaanalysis of the published literature. Pediatrics 1995;96:29-35. [Crossref]  [PubMed]
  5. Behr MA, Small PM. A historical and molecular phylogeny of BCG strains. Vaccine. 1999;17:915-22. [Crossref]  [PubMed]
  6. Oettinger T, Jorgensen M, Ladefoged A, Haslov K, Andersen P. Development of the Mycobacterium bovis BCG vaccine: review of the historical and biochemical evidence for a genealogical tree. Tuber Lung Dis. 1999;79:243-50. [Crossref]  [PubMed]
  7. The BCG World Atlas. 3rd ed. [Link]
  8. Brewer TF. Preventing Tuberculosis with Bacillus Calmette-Guérin Vaccine: A Meta-Analysis of the Literature. Clinical Infectious Diseases. 2000;31:64-7. [Crossref]  [PubMed]
  9. Wilson ME, Fineberg HV, Colditz GA. Geographic latitude and the efficacy of bacillus Calmette-Guérin vaccine. Clin Infect Dis. 1995;20:982-91. [Crossref]  [PubMed]
  10. Aronson NE, Santosham M, Comstock GW, Howard RS, Moulton LH, Rhoades ER, et al. Long-term efficacy of BCG vaccine in American Indians and Alaska natives a 60-year follow-up study. JAMA. 2004;291:2086-91. [Crossref]  [PubMed]
  11. Mangtani P, Nguipdop-Djomo P, Keogh RH, Sterne JAC, Abubakar I, Smith PG, et al. The duration of protection of school-aged BCG vaccination in England: a population based case-control study. Int J Epidemiol. 2018;47:193-201. [Crossref]  [PubMed]
  12. Gökçay G, Beyazova U. İlk Beş Yaşta Çocuk Sağlığı İzlemi, Sosyal Pediatri Derneği Yayınları. İstanbul: Nobel Tıp Yayıncılık; 2017. p. 473-8.
  13. Tuğluoğlu F. Cumhuriyet döneminde verem mücadelesi ve propaganda faaliyetleri. İstanbul Üniversitesi Yakın Dönem Türkiye Araştırmaları Dergisi. 2012;0:13-4.
  14. Irmak H. T.C. Sağlık Bakanlığı Halk Sağlığı Müdürlüğü. Tüberküloz Tanı ve Tedavi Rehberi. Kara F, editor. 2. Baskı. Ankara: Artı6 Medya Tanıtım Matbaa Hizmetleri Ltd. Şti.; 2019. p. 196-202.
  15. T.C. Sağlık Bakanlığı Temel Sağlık Hizmetleri Müdürlüğü. 13.03.2009 Tarihli Genişletilmiş Bağışıklama Programı Genelgesi ve 16.07.2018 Güncellemesi.
  16. Gocmen A, Kiper N, Ertan U, Kalaycı O, Ozcelik U. Is the BCG test of diagnostic value in tuberculosis? Tuber Lung Dis. 1994;75:54-7. [Crossref]  [PubMed]
  17. Black GF, Weir RE, Floyd S, Bliss L, Warndorff DK, Crampin AC, et al. BCG-induced increase in interferon-gamma response to mycobacterial antigens an defficacy of BCG vaccination in Malawi and the UK: two randomised controlled studies. Lancet. 2002;359:1393-401. [Crossref]  [PubMed]
  18. Kaufmann SH. How can immunology contribute to the control of tuberculosis? Nat Rev Immunol. 2001;1:20-30. [Crossref]  [PubMed]
  19. Flynn JL. Immunology of tuberculosis and implications in vaccine development. Tuberculosis (Edinb). 2004;84(1-2):93-101. [Crossref]  [PubMed]
  20. Bass JB, Farer LS, Hopewell PC, O'Brien R, Jacobs RF, Ruben F, et al. Treatment of tuberculosis and tuberculosis infections in adults and children. Am J Respir Crit Care Med. 1994;149(5):1359-74. [Crossref]  [PubMed]  [PMC]
  21. Lange C, Aaby P, Behr MA, Donald PR, Kaufmann SHE, Netea MG, et al. 100 years of Mycobacterium bovis bacille Calmette-Guérin. Lancet Infect Dis. 2022; 22(1):2-12. [Crossref]  [PubMed]
  22. Bellet JS, Prose NS. Skin complications of Bacillus Calmette-Guérin immunization. Curr Opin Infect Dis. 2005;18(2):97-100. [Crossref]  [PubMed]
  23. Dommergues MA, Rocque F, Guy C, Lécuyer A, Jacquet A, Guérin N, et al. Local and regional adverse reactions to BCG vaccination: A 12-month cohort follow-up study. Vaccine. 2009; 27(50):6967-73. [Crossref]  [PubMed]
  24. Yang SY, Chang HS. Bacilli-containing granuloma with subsequent granuloma annulare-like eruptions following Bacillus Calmette-Guérin vaccination. Pediatr Neonatol. 2018;59(5):525-6. [Crossref]  [PubMed]
  25. Kara A, Çiftçi E, Tezer H, Somer A. Aşı ve bağışıklama. 1. Baskı. Ankara: Bizim Matbaa Baskı Hizmetleri San. Tic. AŞ.; 2021. p. 301-28.
  26. Walker SL, Lozewicz S, Sood R, Mann TAN, Campalani E, Hubbard VG. Lupus vulgaris due to Mycobacterium bovis bacillus Calmette-Guérin (BCG) at the site of previous BCG vaccination. Clinical and experimental dermatology. 2008; 34(7):213-5. [Crossref]  [PubMed]  [PMC]
  27. Venkataraman A, Yusuff M, Liebeschuetz S, Riddell A, Prendergast AJ. Management and outcome of Bacille Calmette-Guérin vaccine adverse reactions. Vaccine. 2015;33(41):5470-4. [Crossref]  [PubMed]  [PMC]
  28. Boran C, Coban YK, Sasmaz S, Parmaksiz G. Huge keloid formation after bcg vaccination. Pediatric Dermatology. 2003;20(5):460-460. [Crossref]  [PubMed]
  29. Oğuz F, Müjgan S, Alper G, Alev F, Neyzi O. Treatment of Bacillus Calmette-Guérin-associated lymphadenitis. Pediatr Infect Dis J. 1992;11(10):887-8. [Crossref]  [PubMed]
  30. Santosa A, Diasa A, Cordeiroa A, Cordinhãa C, Lemosb S, Rochac G, et al. Severe Axillary Lymphadenitis After BCG Vaccination: Alert for Primary Immunodeficiencies. J Microbiol Immunol Infect. 2010;43(6):530-7. [Crossref]  [PubMed]
  31. Keijsers RRMC, Bovenschen HJ, Seyger MMB. Cutaneous complication after BCG vaccination: Case report and review of the literature. Journal of Dermatological Treatment. 2010;22(6):315-8. [Crossref]  [PubMed]
  32. Terreri MT, Yamada AF. Osteitis caused by BCG vaccination. Pediatr Radiol. 2008;38:481. [Crossref]  [PubMed]
  33. Lin WL, Chiu NC, Lee PH, Huang AS, Huang FY, Chi H, et al. Management of Bacillus Calmette-Guérin osteomyelitis/osteitis in immunocompetent children-A systematic review. Vaccine. 2015;33(36):4391-7. [Crossref]  [PubMed]
  34. Mascaró JM, Baselga E. Erythema Induratum of Bazin. Dermatologic Clinics. 2008;26(4):439-45. [Crossref]  [PubMed]
  35. Norouzi S, Aghamohammadi A, Mamishi S, Rosenzweig SD, Rezaeib N. Bacillus Calmette-Guérin (BCG) complications associated with primary immunodeficiency diseases. J Infect. 2012;64(6):543-54. [Crossref]  [PubMed]  [PMC]
  36. Marciano BE, Huang CY, Joshi G, Rezaei N, Carvalho BC, Allwood Z, et al. BCG vaccination in patients with severe combined immunodeficiency: complications, risks, and vaccination policies. J Allergy Clin Immunol. 2014; 133(4):1134-41. [Crossref]  [PubMed]  [PMC]
  37. Talbot EA, Perkins MD, Silva SF, Frothingham R. Disseminated bacille Calmette-Guerin disease after vaccination: case report and review. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 1997;24(6):1139-46. [Crossref]  [PubMed]
  38. Sharma SK, Soneja M. HIV & immune reconstitution inflammatory syndrome (IRIS). Indian J Med Res. 2011;134(6):866-77. [Crossref]  [PubMed]  [PMC]
  39. Sharma SK, Dhooria S, Barwad P, Kadhiravan T, Ranjan S, Miglani S, et al. A study of TB-associated immune reconstitution inflammatory syndrome using the consensus case-definition. Indian J Med Res. 2010;131:804-8.